BioSpace News Archive

Leader in Cloud Revenue Management Uncovers the Industry’s Focus on Finding New Efficiencies, Managing Revenue and Changing the Dialog on Drug Pricing

An Independent University of Minnesota Study Calculates the OxyPure® Reduces 99.999% Virus Concentration Within Six Hours

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the third quarter of 2020 on Thursday, November 5, 2020 a

The patent covers key systems and methods for the evaluation of disease onset, disease progression or disease treatment efficacy

Tampa General is proud to announce Stacey Brandt as the Bronze Stevie Award winner. She will be recognized during the 17th annual virtual event.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued an October 2020 Letter to Shareholders

PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today a distribution agreement with Sofregen Medical Inc. for its Silk Voice Injectable Implant.

Perspectum’s new whitepaper clearly outlines how the upfront cost of pre-screening subjects for NASH clinical trial enrollment with non-invasive, MRI-based imaging biomarkers can be significantly offset by the costs saved due to the reduction in total number of biopsies required for trial enrollment.

Applied Medical launches the next advancement of its groundbreaking Voyant Intelligent Energy system – a new algorithm to further enhance clinical performance and patient outcomes

Diaceutics PLC, (AIM: DXRX), today announces the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months.